List of works - Allan C deCamp

Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial

scientific article

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial

scientific article

Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk

scientific article published on 01 November 2019

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials

scientific article published on 22 May 2020

Assessing Vaccine Effects in Hiv-1 Vaccine Trials: Antigenic Maps, Antigen Selection, and Sieve Analysis ⬇️

doctoral thesis by Allan deCamp, University of Washington, 2013

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

scientific article

Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial

scientific article

Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial ⬇️

scientific article published on February 27, 2011

Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies

scientific article

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees

scientific article published on 31 January 2018

HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition

scientific article published on July 2015

Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine

scientific article published on 27 December 2011

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

scientific article (publication date: 5 April 2012)

Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes

scientific article

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

scientific article

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia

scientific article

MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load

scientific article

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial

scientific article published on 8 January 2018

Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention

scientific article published on 06 April 2022

Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants

scientific article

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial

scientific article

Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections

scientific article

Selection of HIV vaccine candidates for concurrent testing in an efficacy trial

scientific article published on 28 January 2016

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.

scientific article published on 17 November 2017

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.

scientific article

Vaccination induces HIV broadly neutralizing antibody precursors in humans ⬇️

journal article published in 2022

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

scientific article

Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses

scientific article

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection

scientific article

List of works by Allan C deCamp

Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial

Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials

Assessing Vaccine Effects in Hiv-1 Vaccine Trials: Antigenic Maps, Antigen Selection, and Sieve Analysis ⬇️

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial

Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial ⬇️

Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees

HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition

Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia

MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial

Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention

Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial

Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections

Selection of HIV vaccine candidates for concurrent testing in an efficacy trial

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.

Vaccination induces HIV broadly neutralizing antibody precursors in humans ⬇️

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection